HUP0104857A2 - Új rákkezelési módszerek - Google Patents

Új rákkezelési módszerek

Info

Publication number
HUP0104857A2
HUP0104857A2 HU0104857A HUP0104857A HUP0104857A2 HU P0104857 A2 HUP0104857 A2 HU P0104857A2 HU 0104857 A HU0104857 A HU 0104857A HU P0104857 A HUP0104857 A HU P0104857A HU P0104857 A2 HUP0104857 A2 HU P0104857A2
Authority
HU
Hungary
Prior art keywords
cell lines
prostate cancer
cancer treatments
new cancer
combination
Prior art date
Application number
HU0104857A
Other languages
English (en)
Inventor
Angus George Dalgleish
Peter Michael Smith
Andrew Derek Sutton
Anthony Ian Walker
Original Assignee
Onyvax Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyvax Limited filed Critical Onyvax Limited
Publication of HUP0104857A2 publication Critical patent/HUP0104857A2/hu
Publication of HUP0104857A3 publication Critical patent/HUP0104857A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

A tal lm ny t rgy t egy sejtvonalak specifikus kombin ciój ból llótermék képezi, mely allogén immunter pi s szerként szolg l a hum nprosztatar k kezelésében. Az immunter pi s szer heterogenit sa"sszeillik a célzott prosztatar k antigén-profilj val és a befogadókata lehetséges TAA-k és TSA-k sok képviselőjével immuniz lja, melyek abetegség kül"nb"ző st diumaiban fejeződnek ki. A tal lm ny egy vakcint szolg ltat, mely elsődleges vagy metaszt zisos prosztatar kbólbiopszi val vett sz"vetből sz rmazó h rom kül"nb"ző sejtvonal kombinciój ból ll. A sejtvonalakat hal los dózisú, 50-300 Gy gamma sug rralbesug rozz k, hogy biztosíts k a sejtek szaporod sképtelenségét. Ó
HU0104857A 1998-12-10 1999-12-09 New cancer treatments HUP0104857A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9827103.4A GB9827103D0 (en) 1998-12-10 1998-12-10 New cancer treatments
PCT/GB1999/004135 WO2000033870A2 (en) 1998-12-10 1999-12-09 New cancer treatments

Publications (2)

Publication Number Publication Date
HUP0104857A2 true HUP0104857A2 (hu) 2002-04-29
HUP0104857A3 HUP0104857A3 (en) 2004-04-28

Family

ID=10843925

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104857A HUP0104857A3 (en) 1998-12-10 1999-12-09 New cancer treatments

Country Status (19)

Country Link
US (1) US6699483B1 (hu)
EP (1) EP1137434B1 (hu)
JP (1) JP4607330B2 (hu)
KR (1) KR100612552B1 (hu)
AT (1) ATE412425T1 (hu)
AU (1) AU777969B2 (hu)
CA (1) CA2354046C (hu)
CZ (1) CZ20012033A3 (hu)
DE (1) DE69939837D1 (hu)
ES (1) ES2315024T3 (hu)
GB (1) GB9827103D0 (hu)
HU (1) HUP0104857A3 (hu)
IL (2) IL143295A0 (hu)
MX (1) MXPA01005815A (hu)
NO (1) NO326035B1 (hu)
NZ (1) NZ512005A (hu)
PL (1) PL348829A1 (hu)
WO (1) WO2000033870A2 (hu)
ZA (1) ZA200104163B (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2404388C (en) * 2000-04-01 2010-06-15 Onyvax Limited New prostate cell lines
US6977072B2 (en) 2000-10-27 2005-12-20 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
JP2006507214A (ja) * 2002-02-22 2006-03-02 イントラセル・リソーシーズ・エル・エル・シー 無菌の、免疫原性の、非腫瘍形成性の腫瘍細胞組成物及び方法
US7176022B2 (en) * 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
US20050019336A1 (en) 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment
WO2005023328A2 (en) * 2003-08-26 2005-03-17 Becton Dickinson And Company Methods for intradermal delivery of therapeutics agents
US9050352B2 (en) 2003-10-16 2015-06-09 Stephen John Ralph Immunomodulating compositions and uses therefor
US8257715B1 (en) 2004-08-26 2012-09-04 University Of Notre Dame Tissue vaccines and uses thereof
ES2732623T3 (es) 2005-01-06 2019-11-25 Innate Pharma Sa Tratamientos y métodos de combinación anti-KIR
US9308252B2 (en) * 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US8778362B2 (en) 2005-10-27 2014-07-15 University Of Notre Dame Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof
US8802113B2 (en) * 2005-10-27 2014-08-12 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US8778360B2 (en) * 2005-10-27 2014-07-15 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
GB0601598D0 (en) 2006-01-26 2006-03-08 Stathopoulos Apostolos Method
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
WO2010053772A2 (en) 2008-10-29 2010-05-14 The Regents Of The University Of California Disease-associated antigens and methods of use thereof
JP5797190B2 (ja) 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス， インコーポレイテッド ワクチン免疫療法
CN103097543A (zh) 2009-12-08 2013-05-08 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
US8846059B2 (en) 2009-12-08 2014-09-30 University Of Notre Dame Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer
US20110150934A1 (en) * 2009-12-18 2011-06-23 University Of Notre Dame Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer
CN105850981B (zh) * 2016-04-29 2018-07-20 绍兴市人民医院 冻存肿瘤组织的方法
CN105850982B (zh) * 2016-04-29 2018-08-17 绍兴市人民医院 一种新型组织冻存液
US20220282220A1 (en) * 2019-07-24 2022-09-08 Sl Bigen Inc. Method for preparation of immortalized stem cell line and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
EP0869803B1 (en) * 1995-12-28 2003-04-16 The Johns Hopkins University School Of Medicine Allogeneic paracrine cytokine tumor vaccines
DE69721731T2 (de) 1996-02-02 2004-03-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immortalisierte menschliche prostata-epithelzellen und klone und ihre verwendungen zur untersuchung und therapie von prostata-krebs
WO2000026676A1 (en) * 1998-11-03 2000-05-11 Cell Genesys, Inc. Cancer-associated antigens and methods of their identification
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments

Also Published As

Publication number Publication date
US6699483B1 (en) 2004-03-02
KR20010090873A (ko) 2001-10-19
ES2315024T3 (es) 2009-03-16
HUP0104857A3 (en) 2004-04-28
EP1137434A2 (en) 2001-10-04
AU777969B2 (en) 2004-11-04
KR100612552B1 (ko) 2006-08-11
JP4607330B2 (ja) 2011-01-05
DE69939837D1 (de) 2008-12-11
MXPA01005815A (es) 2003-04-02
CA2354046A1 (en) 2000-06-15
WO2000033870A3 (en) 2000-08-17
NO326035B1 (no) 2008-09-01
PL348829A1 (en) 2002-06-17
ZA200104163B (en) 2002-02-04
IL143295A (en) 2006-04-10
ATE412425T1 (de) 2008-11-15
NO20012818L (no) 2001-06-07
IL143295A0 (en) 2002-04-21
CA2354046C (en) 2011-02-15
NO20012818D0 (no) 2001-06-07
WO2000033870A2 (en) 2000-06-15
AU1668700A (en) 2000-06-26
JP2002531521A (ja) 2002-09-24
GB9827103D0 (en) 1999-02-03
EP1137434B1 (en) 2008-10-29
CZ20012033A3 (cs) 2001-10-17
NZ512005A (en) 2004-01-30

Similar Documents

Publication Publication Date Title
HUP0104857A2 (hu) Új rákkezelési módszerek
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
Nicholson et al. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis.
CY1111147T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
MXPA05014152A (es) Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos.
BG101284A (en) Compounds and methods for cancer treatment
DE69332643D1 (de) Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus
BG66293B1 (en) Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
IL146125A0 (en) Novel quinones as disease therapies
ATE287958T1 (de) Verbesserte krebstherapie
WO2003039591A3 (de) Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
HUP0104568A2 (hu) Humán prosztata sejtvonalak a daganatok kezelésében
WO2004104591A3 (en) Improvements to gamma delta t cell-mediated therapy
WO2000033871A3 (en) Use of human prostate tumour cell lines in cancer treatment
GB2419530A (en) Human prostate cell lines in cancer treatment
Mackie Emerging Cancer Therapeutics
ATE291620T1 (de) Mammakarzinom-assoziiertes gen
Darendeliler et al. A phase II trial, feasibility of combination of daily cisplatinum and accelerated radiotherapy via concomitant boost in stage III non-small cell lung cancer
Tyroler Panama: Note On Alternatives For Modernization Of Panama Canal
Hall Combination chemoradiotherapy for bladder cancer with bladder sparing
Werden et al. Auroral X-ray images during a pulsation event
McNamee Cancer responds better to combined treatments.
Fabian Variability from pair atmospheres.
Coghlan Race is on to stop human cloning
Vikram Towards consistent local control in nasopharyngeal carcinoma: the role of elective iodine-125 brachytherapy boost.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees